Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

SIMPLE SUMMARY: Neuroendocrine neoplasms have been usually described as infrequent tumors, but their incidence has been rising over time. [(177)Lu]Lu-DOTA-TATE (PRRT-Lu) was approved by the European Medicines Agency and by the Food and Drug Administration as the first radiopharmaceutical for peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: del Olmo-García, Maria I., Prado-Wohlwend, Stefan, Bello, Pilar, Segura, Angel, Merino-Torres, Juan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833790/
https://www.ncbi.nlm.nih.gov/pubmed/35158852
http://dx.doi.org/10.3390/cancers14030584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833790/
https://www.ncbi.nlm.nih.gov/pubmed/35158852
http://dx.doi.org/10.3390/cancers14030584

Ejemplares similares